WAVE Life Sciences (NASDAQ: WVE) and RXi Pharmaceuticals Corporation (NASDAQ:RXII) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for WAVE Life Sciences and RXi Pharmaceuticals Corporation, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WAVE Life Sciences 0 0 5 0 3.00
RXi Pharmaceuticals Corporation 0 0 0 0 N/A

WAVE Life Sciences presently has a consensus target price of $40.00, indicating a potential upside of 72.41%. RXi Pharmaceuticals Corporation has a consensus target price of $1.71, indicating a potential upside of 223.25%. Given RXi Pharmaceuticals Corporation’s higher probable upside, analysts clearly believe RXi Pharmaceuticals Corporation is more favorable than WAVE Life Sciences.

Risk & Volatility

WAVE Life Sciences has a beta of -0.1, meaning that its stock price is 110% less volatile than the S&P 500. Comparatively, RXi Pharmaceuticals Corporation has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Valuation and Earnings

This table compares WAVE Life Sciences and RXi Pharmaceuticals Corporation’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
WAVE Life Sciences $2.42 million 266.13 -$79.63 million ($3.35) -6.93
RXi Pharmaceuticals Corporation N/A N/A -$9.40 million ($1.32) -0.40

RXi Pharmaceuticals Corporation has higher revenue, but lower earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than RXi Pharmaceuticals Corporation, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

69.6% of WAVE Life Sciences shares are held by institutional investors. Comparatively, 1.7% of RXi Pharmaceuticals Corporation shares are held by institutional investors. 53.0% of WAVE Life Sciences shares are held by company insiders. Comparatively, 5.7% of RXi Pharmaceuticals Corporation shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares WAVE Life Sciences and RXi Pharmaceuticals Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
WAVE Life Sciences -3,375.12% -55.19% -45.21%
RXi Pharmaceuticals Corporation N/A -155.48% -102.55%

Summary

WAVE Life Sciences beats RXi Pharmaceuticals Corporation on 6 of the 11 factors compared between the two stocks.

WAVE Life Sciences Company Profile

WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. The nucleic acid therapeutics, which the Company is developing are stereopure. A stereopure oligonucleotide includes molecules with atoms arranged in three-dimensional orientations at each linkage. The Company has three programs in Huntington’s disease (HD) and Duchenne Muscular Dystrophy (DMD), and three additional development candidates.

RXi Pharmaceuticals Corporation Company Profile

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator. Its clinical development programs include RXI-109, an sd-rxRNA, for the treatment of dermal and ocular scarring, and Samcyprone for the treatment of such disorders as warts, alopecia areata, non-malignant skin tumors and cutaneous metastases of melanoma. Its pipeline is focused on approximately three areas, including dermatology, ophthalmology and cosmetic product development. Its RNAi therapies are designed to silence, or down-regulate, the expression of a specific gene that may be over-expressed in a disease condition and its immunotherapy agent treats diseases by inducing, enhancing or suppressing an immune response.

Receive News & Ratings for WAVE Life Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WAVE Life Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.